Why Amgen Stock Popped by 4% Today
Key Takeaways
Ing quite encouraging news from the laboratory on Monday, Amgen (AMGN -1. 78%) was something of a stock market favorite the ing day. Its s closed the trading session more than...
Article Overview
Quick insights and key information
2 min read
Estimated completion
investment
Article classification
July 1, 2025
06:55 PM
The Motley Fool
Original publisher
Ing quite encouraging news from the laboratory on Monday, Amgen (AMGN -1. 78%) was something of a stock market favorite the ing day
Its s closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the development
With that price rise, Amgen easily beat the S&P 500 index, which slid by 0
Cancer drug does well in testing That news concerned Amgen's investigational stomach cancer drug, bemarituzumab
The company announced Monday that, in combination with chemotherapy, the treatment met its primary endpoint of of overall survival for the patients tested in a phase 3 clinical trial
It compared favorably to the results of patients only taking a placebo and receiving chemotherapy
Image source: Getty Images
The study had an enrollment of 547 patients who suffered from certain types of unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer
Amgen pointed out in its press release on the trial's results that gastric cancer is the fifth-leading cause of cancer-related death in the world, with over 650,000 fatalities
The two immediate analyst reactions to the news were both positive and complimentary
Piper Sandler's David Amsellem reiterated his overweight (i. , buy) recommendation and $328 per price target
According to reports, Amsellem said that while there were some concerns with the study, its results were positive, and Amgen could have quite a successful drug on its hands
Potential blockbuster
As cancer is a persistent and tough challenge, any advancement in its treatment is cause for optimism
While Amgen could have vided more details of the study (it pledged to do so in an unspecified presentation in the near future), the rough outlines of bemarituzumab are encouraging
The company might very well be on the cusp of success with the drug
Eric Volkman has no position in any of the stocks mentioned
The Motley Fool has positions in and recommends Amgen
The Motley Fool has a disclosure policy.
Related Articles
More insights from FinancialBooklet